Related Experiment Video
Updated: Jun 16, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Double-regulated oncolytic adenovirus-mediated interleukin-24 overexpression exhibits potent antitumor activity on
Na Wei1, Jun Kai Fan, Jin Fa Gu
1Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Abstract:
Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), identified by subtraction hybridization in the mid-1990s, is a potent gene therapeutic for cancer. Using a replication-deficient adenovirus as vector, it provokes apoptosis in diverse cancer cells without harming normal cells or tissues. To exploit the anticancer capability of IL-24 to the best, in this study, we generated a novel gene-virotherapy agent MUD55-IL-24, utilizing a replication-competent oncolytic adenovirus MUD55 as the gene delivery vector. It was documented that MUD55-IL-24 exhibited much stronger antitumor activity on gastric carcinoma both in vitro and in vivo, and its safety was comparable to the replication-deficient adenovirus Ad-IL-24. The unique properties of IL-24, including apoptosis induction, antiangiogenesis, and antimigration, were all significantly enhanced in MUD55-IL-24. After looking into the underlying mechanism, we found that intracellular ROS (Reactive Oxygen Species) generation may have caused the induction of apoptosis, mitochondrial dysfunction, and the activation of caspases in MUD55-IL-24-infected SG-7901 cells. Taken together, these results suggest that MUD55-IL-24 may be able to provide a potential strategy for future treatment of human gastric carcinoma.
Insights
A novel gene-virotherapy agent, MUD55-IL-24, shows enhanced antitumor activity against gastric carcinoma. This interleukin-24 (IL-24) based therapy induces apoptosis and offers a potential new treatment strategy.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Molecular oncology
Background:
- Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a promising cancer therapeutic agent.
- IL-24 delivered via replication-deficient adenovirus induces cancer cell apoptosis without harming normal cells.
- Exploiting IL-24's full potential requires advanced delivery systems.
Purpose of the Study:
- To develop a novel gene-virotherapy agent, MUD55-IL-24, using a replication-competent oncolytic adenovirus (MUD55) as the vector.
- To evaluate the enhanced antitumor efficacy and safety of MUD55-IL-24 against gastric carcinoma.
- To investigate the underlying mechanisms of MUD55-IL-24-induced cancer cell death.
Main Methods:
- Generation of MUD55-IL-24 using MUD55 oncolytic adenovirus vector.
- In vitro and in vivo assessment of MUD55-IL-24's antitumor activity on gastric carcinoma.
- Analysis of IL-24 properties (apoptosis, antiangiogenesis, antimigration) and intracellular mechanisms (ROS, mitochondrial dysfunction, caspases).
Main Results:
- MUD55-IL-24 demonstrated significantly stronger antitumor effects on gastric carcinoma compared to Ad-IL-24.
- The safety profile of MUD55-IL-24 was comparable to the replication-deficient Ad-IL-24.
- Enhanced apoptosis, antiangiogenesis, and antimigration properties were observed with MUD55-IL-24.
- Intracellular ROS generation, mitochondrial dysfunction, and caspase activation were identified as key mechanisms in MUD55-IL-24-treated cells.
Conclusions:
- MUD55-IL-24 represents a potent gene-virotherapy agent with superior antitumor activity against gastric carcinoma.
- The enhanced efficacy is linked to increased apoptosis induction via ROS generation and mitochondrial pathways.
- MUD55-IL-24 holds promise as a potential therapeutic strategy for human gastric carcinoma.
